Type 2 Diabetes Remission

Remission in type 2 diabetes means blood sugar has fallen below the diagnostic threshold and remains there without glucose-lowering medication. The usual operational definition in modern trials is HbA1c < 6.5% (48 mmol/mol) sustained off medication for at least 12 weeks.

Remission is explicitly not a cure — the metabolic disease process can resume, and durability beyond trial windows is still an open question across most published protocols.

What induces remission

The best evidence so far points at substantial weight loss, achieved most reliably via a very-low-calorie / low-energy diet (typically 800–900 kcal/day for ~12 weeks) followed by a structured maintenance phase. Earlier UK trials (DiRECT and its lineage) established this for broader T2D populations. More recent work layers in structured exercise — aerobic + resistance — with two aims:

1. Preserve fat-free mass / muscle during rapid weight loss, reducing long-term Sarcopenia risk if weight returns.
2. Improve cardiovascular fitness, insulin sensitivity, and patient-reported well-being alongside glucose control.

The RESET for Remission trial (Dasgupta/Yates, 2026, Lancet Regional Health — Americas) is the first randomised trial of this combined protocol specifically in early-onset T2D (EOT2D, under-45), hitting 54% remission vs 4% usual care at 24 weeks in a multi-ethnic UK/Canada population.

Why early-onset is a distinct problem

Type 2 diabetes diagnosed before age 45 is biologically more aggressive than later-onset T2D: faster β-cell decline, earlier cardiovascular and renal complications, and a shorter life expectancy relative to peers. Because people with EOT2D accumulate more years of elevated blood glucose, interventions that work early carry outsized lifetime value — this is the explicit motivation for the RESET trial.

Open questions

• Durability. How long does remission hold after participants exit clinical supervision? Most published protocols (RESET included) have not tested beyond 12 months.
• Weight regain and body composition. Lost weight is often regained with a worse fat/muscle ratio than the pre-trial baseline, which is why muscle-preservation during the weight-loss phase is a central design concern of newer protocols.
• Scalability. 800–900 kcal/day with supervised twice-weekly exercise is resource-intensive. Real-world primary-care implementation is unproven at scale.
• Pregnancy populations. RESET's authors flag EOT2D women planning pregnancy as a priority use case — a drug-free remission avoids the contraindications attached to several glucose-lowering medications in pregnancy.

Related

• RESET for Remission Trial (ScienceDaily) — 2026 trial, EOT2D, combined diet + exercise, 54% remission at 24 weeks.